Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Rhea-AI Summary
Nephros (NASDAQ: NEPH) launched the 19-Series PFAS Filter on October 8, 2025, a point-of-use filter designed to reduce Total PFAS in potable water.
The filter is independently tested to NSF Standards 42 and 53, validated to reduce Total PFAS including PFOA and PFOS, and also reduces lead, asbestos, cysts, chlorine, taste, and odor. Product specs include a 3,145-gallon capacity and 1.63 GPM flow rate. Target customers include healthcare, daycares, education, foodservice, and manufacturing. Performance data is available on the product page.
Positive
- Independently tested to NSF Standards 42 and 53
- Validated reduction of Total PFAS including PFOA and PFOS
- Reduces multiple hazards: lead, asbestos, cysts, chlorine
- 3,145-gallon capacity with 1.63 GPM flow rate
- Targeted for critical sectors: healthcare, daycares, education
Negative
- None.
Insights
New point-of-use filter expands Nephros’s portfolio to address Total PFAS alongside multiple contaminants.
Nephros launched the 19-Series PFAS Filter on
The business mechanism is simple: product expansion into a regulated, high-attention contaminant class increases addressable demand where safer drinking water is required. The announcement remains factual and technical; it does not disclose pricing, contracts, production capacity, or quantified market adoption, which are key dependencies for commercial impact.
Risks and dependencies include real-world performance versus lab validation, channel acceptance in healthcare and foodservice, and timing/scale of regulatory adoption that drive procurement. Monitor independent performance reports, any procurement announcements, and published NSF test data over the next 6-18 months to gauge commercial traction.
New 19-Series solution targets wide range of chemical contaminants
SOUTH ORANGE, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros’ portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention.
PFAS, sometimes referred to as “forever chemicals,” are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health.
“Unlike most filters that only address PFOA and PFOS, the Nephros 19-Series PFAS Filter has been independently tested to reduce Total PFAS, offering protection against a much broader spectrum of contaminants,” said Robert Banks, President & CEO of Nephros. “By combining PFAS reduction with protection against lead, asbestos, and other hazards, we believe the 19-Series PFAS Filter helps set a new benchmark in support of safer, more reliable drinking water.”
Key Features of the Nephros 19-Series PFAS Filter
- Independently tested to NSF Standards 42 and 53
- Validated reduction of Total PFAS, including PFOA and PFOS
- Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste,
and odor - 3,145-gallon capacity with a 1.63 GPM flow rate
- Provides long-term protection against persistent, health-threatening waterborne contaminants
The Nephros 19-Series PFAS filter is ideal for industries and facilities where water safety is critical, including healthcare, daycares, education, foodservice, and manufacturing. For more information, including performance data, please visit the Nephros 19-Series Filter product page on our website.
About Nephros
Nephros is a leading provider of filtration products to medical and commercial markets, offering a wide range of solutions that deliver superior filtration performance. With advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.
For more information about Nephros, visit nephros.com
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected benefits of the 19-Series PFAS Filter and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ dependence on third-party manufacturers, distributors and researchers, changes in business and competitive conditions and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202
robert.banks@nephros.com
Judy Krandel, CFO
Nephros, Inc.
(201) 343-5202
judy.krandel@nephros.com
FAQ
What does Nephros announce about PFAS on October 8, 2025 for NEPH?
Is the Nephros 19-Series PFAS Filter independently tested for NEPH products?
What contaminants does the NEPH 19-Series PFAS Filter reduce?
What are the capacity and flow specifications for the NEPH 19-Series PFAS Filter?
Which industries is the NEPH 19-Series PFAS Filter intended for?
Where can investors find performance data for the NEPH 19-Series PFAS Filter?
